Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies

References

• World Health Organization. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol. Rec.40, 331–339 (2002).
   Google Scholar
• Van den Bruel A, Haj-Hassan T, Thompson M, Buntinx F, Mant D. European research network on recognising serious infection investigators. Lancet375, 834–845 (2010).
   PubMed Web of Science ®Google Scholar
• Cummings KC, Louie J, Probert WS et al. Increased detection of meningococcal infections in California using a polymerase chain reaction assay. Clin. Infect. Dis.46, 1124–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Buysse CM, Vermunt LC, Raat H et al. Surviving meningococcal septic shock in childhood: long-term overall outcome and the effect on health-related quality of life. Crit. Care14, R124 (2010).
   PubMedGoogle Scholar
• Safadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurolog. Res.32, 263–271 (2010).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden MCJ. Meningococcal vaccine and herd immunity: lessons learned from serogroup C conjugate vaccine programs. Expert Rev. Vaccines8(7), 851–861 (2009).
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin. Infect. Dis.50, 184–191 (2010).
   PubMed Web of Science ®Google Scholar
• Racloz VN, Luiz SJD. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect. Dis.10, 175 (2010).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Epidemics of meningococcal disease, African meningitis belt. Wkly. Epidemiol. Rec.76, 282–288 (2001).
   PubMedGoogle Scholar
• Pollard AJ, Maiden MC. Epidemic meningococcal disease in sub-Saharan Africa – towards a sustainable solution? Lancet Infect. Dis.3, 68–70 (2003).
   PubMed Web of Science ®Google Scholar
• Decosas J, Koama JPT. Chronicle of an outbreak foretold: meningococcal meningitis W-135 in Burkina Faso. Lancet Infect. Dis.2, 763–765 (2002).
   PubMed Web of Science ®Google Scholar
• Traoré Y, Njanpop-Lafourcade BM, Adjogble KL et al. The rise and fall of epidemic Neisseria meningitidis serogroup W-135 meningitis in Burkina Faso, 2002–2005. Clin. Infect. Dis.43, 817–822 (2006).
   PubMed Web of Science ®Google Scholar
• Mutonga DM, Pimental G, Muindi J et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005–2006. Am. J. Trop. Med. Hyg.80, 619–624 (2009).
   PubMed Web of Science ®Google Scholar
• Materu S, Cox HS, Isaakidis P, Baruani B, Ogaro T, Caugant DA. Serogroup X in meningococcal disease, Western Kenya. Emerg. Infect. Dis.13, 944–945 (2007).
   PubMed Web of Science ®Google Scholar
• Delrieu I, Yaro S, Tamekloé TAS et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE6, e19513 (2011).
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis.44, 657–663 (2007).
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine27S, B51–B63 (2009).
   Google Scholar
• Ni JD, Jin YH, Dai B et al. Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China. Postrad. Med. J.84, 87–92 (2008).
   PubMed Web of Science ®Google Scholar
• Nair D, Dawar R, Deb M et al. Outbreak of meningococcal disease in and around New Delhi, India, 2005–2006: a report from a tertiary care hospital. Epidemiol. Infect.137, 570–576 (2009).
   PubMed Web of Science ®Google Scholar
• Jhamb U, Chawla V, Khanna S. Clinical profile of group A meningococcal outbreak in Delhi. Ind. Pediatr.46, 794–796 (2009).
   PubMed Web of Science ®Google Scholar
• Memish ZA, Goubeaud A, Bröker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. J. Infect. Pub. Health3, 143–151 (2010).
   PubMedGoogle Scholar
• Chiappini E, Venturini E, Bonsignori F, Galli L, de Martino M. Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr.99, 1609–1614 (2010).
   PubMed Web of Science ®Google Scholar
• Finn A, Clarke E, Mytton J. Adolescent immunisation: the next big thing? Arch. Dis. Child.96(6), 497–499 (2011).
   PubMed Web of Science ®Google Scholar
• Ford CA, English A, Davenport AF, Stinnett AJ. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues. J. Adolesc. Health44, 568–574 (2009).
   PubMed Web of Science ®Google Scholar
• Perrett KP, Winter AP, Kibwana E et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999–2000 and response to a booster: a Phase 4 clinical trial. Clin. Infect. Dis.50, 1601–1610 (2010).
   PubMed Web of Science ®Google Scholar
• Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med. J. Aust.186, 108–109 (2007).
   PubMed Web of Science ®Google Scholar
• Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics23, 855–874 (2005).
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R. Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr. Infect. Dis. J.28, 220–224 (2009).
   PubMed Web of Science ®Google Scholar
• Grimprel E. Rationale of recommendations for universal immunization against meningococcus C in France. Antibiotiques12, 249–253 (2010).
   Google Scholar
• Kafetzis DA, Stamboulidis KN, Tzanakaki G et al. Meningococcal group C disease in Greece during 1993–2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin. Microbiol. Infect.13, 550–552 (2007).
   PubMed Web of Science ®Google Scholar
• de Greeff C, de Melker HE, Spanjaard L et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J.25, 79–80 (2006).
   PubMed Web of Science ®Google Scholar
• de Voer RM, van der Klis FRM, Niers LEM et al. Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in The Netherlands: an age group at risk? Clin. Vaccine Immunol.16, 1521–1523 (2009).
   PubMedGoogle Scholar
• Larrauri A, Cano R, García M, de Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine23, 4097–4100 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines: Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep.60, 72–76 (2011).
   PubMedGoogle Scholar
• Miller E, Salisbury DM, Ramsay ME. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20, S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Harrison LH, Mohan N, Kirkpatrick P. Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat. Rev. Drug Discov.9, 429–430 (2010).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur. J. Clin. Microbiol. Infect. Dis.29(3), 259–267 (2010).
   PubMed Web of Science ®Google Scholar
• Pace D. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. Curr. Opin. Mol. Ther.11(6), 692–706 (2009).
   PubMedGoogle Scholar
• Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun. Dis. Pub. Health5, 220–225 (2002).
   PubMedGoogle Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet346, 365–367 (2004).
   Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated post licensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol.17, 840–847 (2010).
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197, 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• de Voer RM, Mollema L, Schepp RM et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS One5, e12144 (2010).
   PubMed Web of Science ®Google Scholar
• Deghmane AE, Parent du Chatelet I, Szatanik M et al. Emergence of new virulent Neisseria meningitidis serogroup C sequence 11 isolates in France. J. Infect. Dis.202, 247–250 (2010).
   PubMed Web of Science ®Google Scholar
• Caron F, du Chatelet IP, Leroy JP et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect. Dis.11, 455–463 (2011).
   PubMed Web of Science ®Google Scholar
• Safadi MAP, Barros AP. Meningococcal conjugate vaccines: efficacy and new combinations. J. Pediatr. (Rio J.).82, S35–S44 (2006).
   PubMedGoogle Scholar
• Patel M. Meningococcal disease in Australia: looking at the past, thinking of the future. Commun. Dis. Intell.21, 233–236 (1997).
   PubMedGoogle Scholar
• Simpkins D, Wood N, Jelfs J et al. Modern trends in mortality from meningococcal disease in Australia. Pediatr. Infect. Dis. J.28, 1119–1120 (2009).
   PubMed Web of Science ®Google Scholar
• Australian meningococcal surveillance programme. Annual report of the Australian meningococcal surveillance programme, 2009. Commun. Dis. Intell.34, 291–302 (2010).
   PubMedGoogle Scholar
• De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine. A 7-year follow-up in Quebec, Canada. Pediatr. Infect. Dis. J.30, 566–569 (2011).
   PubMed Web of Science ®Google Scholar
• Nolan T, Lambert S, Marshall H et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine25, 8487–8499 (2007).
   PubMed Web of Science ®Google Scholar
• Sosa J, Llanes R, Guzman D et al. Typing and susceptibility to penicillin of Neisseria meningitidis isolated from patients in Cuba (1993–1999). Mem. Inst. Oswaldo Cruz96, 523–525 (2001).
   PubMed Web of Science ®Google Scholar
• Climent Y, Urwin R, Yero D et al. The genetic structure of Neisseria meningitidis populations in Cuba before and after the introduction of a serogroup BC vaccine. Infect. Genet. Evol.10, 546–554 (2010).
   PubMed Web of Science ®Google Scholar
• Pérez Rodríguez A, Dickinson F, Baly A, Martin R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo Cruz94, 433–440 (1999).
   PubMed Web of Science ®Google Scholar
• Laforce FM, Konde K, Viviani S, Préziosi MP. The meningitis vaccine project. Vaccine3, A97–A100 (2007).
   Google Scholar
• Sow SO, Okoko BJ, Diallo A et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. NEJM364, 2293–2304 (2011).
   PubMed Web of Science ®Google Scholar
• Taha MK, Achtman M, Alonso JM et al. Serogroup W-135 meningococcal disease in Hajj pilgrims. Lancet356, 2159 (2000).
   PubMed Web of Science ®Google Scholar
• Hoek M, Hanquet G, Heuberger S et al. European Union Invasive Bacterial Infections Surveillance Network (EU-IBIS). A European survey on public health policies for managing cases of meningococcal disease and their contacts. Euro. Surveill.13(10), pii: 8060 (2008).
   Google Scholar
• Lennon D, Gellin B, Hood D et al. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis. J.11, 617–623 (1992).
   PubMed Web of Science ®Google Scholar
• Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. J. Paediatr. Child Health37, S13–S19 (2001).
   PubMedGoogle Scholar
• Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol.38(2), 413–418 (2009).
   PubMed Web of Science ®Google Scholar
• Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin. Infect. Dis.49, 597–605 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson C, Lennon DR, Sotutu VT et al. Phase 2 meningococcal B vesicle vaccine trial in New Zealand infants. Arch. Dis. Child.94, 745–751 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson C, Lennon D, Wong S et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch. Dis. Child.96, 744–751 (2011).
   PubMed Web of Science ®Google Scholar
• Caugant DA, Froholm LO, Bovre K et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl Acad. Sci. USA83, 4927–4931 (1986).
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21, 734–737 (2003).
   PubMed Web of Science ®Google Scholar
• Borrow R, Aaberge IS, Santos GF et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12, 970–976 (2005).
   PubMedGoogle Scholar
• Stefanelli P. Emerging resistance in Neisseria meningitidis and Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther.9(2), 237–244 (2011).
   PubMed Web of Science ®Google Scholar
• Krause G, Blackmore C, Wiersma S, Lesneski C, Gauch L, Hopkins RS. Mass vaccination campaign following community outbreak of meningococcal disease. Emerg. Infect. Dis.8, 1398–1403 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor-Robinson D, Elders K, Milton B, Thurston H. Students’ attitudes to the communications employed during an outbreak of meningococcal disease in a UK school: a qualitative study. J. Pub. Health32(1), 32–37 (2010).
   PubMed Web of Science ®Google Scholar
• Moore PS, Reeves MW, Schwartz B, Gellin BG, Broome CV. Intercontinental spread of an epidemic of group A Neisseria meningitidis strain. Lancet2, 260–263 (1989).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W-135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin. Infect. Dis.36, 679–683 (2003).
   PubMed Web of Science ®Google Scholar
• Jolley KA, Wilson DJ, Driz P, McVean G, Maiden MC. The influence of mutation, recombination, population history, and selection on patterns of genetic diversity in Neisseria meningitidis. Mol. Biol. Evol.22, 562–569 (2005).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Barkham TM, Chew SK, Paton NI. Absence of Neisseria meningitidis W-135 electrophoretic type 37 during the Hajj, 2002. Emerg. Infect. Dis.9, 734–737 (2003).
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis.14, e197–e209 (2010).
   PubMed Web of Science ®Google Scholar
• McIntosh EDG, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev. Vaccines10(1), 109–129 (2011).
   PubMed Web of Science ®Google Scholar
• Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control of pneumococcal disease in the UK – impact of vaccination. J. Med. Microbiol.60(Pt 1), 1–8 (2011).
   PubMed Web of Science ®Google Scholar
• Huang SS, Hinrichsen VL, Stevenson AR et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics124, e1–e11 (2009).
   PubMed Web of Science ®Google Scholar
• Parent du Châtelet I, Taha MK, Lepoutre A et al. Meningococcal invasive infections in France in 2006. Bull. Epidemiol. Hebd.51–52, 437–441 (2007).
   Google Scholar
• Ortega-Sanchez IR, Meltzer MI, Shepard C et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin. Infect. Dis.46, 1–13 (2008).
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197, 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• Fernández S, Arreaza I, Santiago I et al. Impact of meningococcal vaccination with combined serogroups A and C polysaccharide vaccine on carriage of Neisseria meningitidis C. J. Med. Micro.52, 75–77 (2003).
   PubMed Web of Science ®Google Scholar
• Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine29, 1968–1973 (2011).
   PubMed Web of Science ®Google Scholar
• Zollinger WD, Poolman JT, Maiden MC. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev. Vaccines10(5), 559–561 (2011).
   PubMed Web of Science ®Google Scholar
• Harris SL, Zhu D, Murphy E et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum. Vaccin.7, 68–74 (2011).
   PubMed Web of Science ®Google Scholar
• Thulin Hedberg S, Törös B, Fredlund H et al. Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Eur. Surveill.16(23), 19885 (2011).
   PubMedGoogle Scholar
• Davila S, Wright VJ, Khor CC et al. International Meningococcal genetics consortium. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet.42, 771–776 (2010).
   Google Scholar